铜对TOCP的神经毒性的神经保护作用 in vivo
Brenda Rosales-Castro1, Isabel Bravo-Ontiveros1, Keyla Betanzos-Rau1
1Laboratorio de Neuroprotección, Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Mexico.
Chemico-biological interactions
|April 25, 2025
概括
铜 (II) 通过保留神经病向酶 (NTE) 活性,对有机诱导的延迟多神经病 (OPIDP) 产生神经保护作用. 这一发现为OPIDP提供了潜在的治疗途径,该疾病目前缺乏有效的治疗方法.
科学领域:
- 神经毒理学 神经毒理学
- 环境健康 环境健康
- 生物化学 生物化学
背景情况:
- 由有机引起的延迟性多神经病变 (OPIDP) 是一种严重的神经毒性综合征,由三正酸 (TOCP) 引起.
- OPIDP的特点是抑制神经病的向雌激酶 (NTE),并导致神经系统缺陷,如和.
- 目前,OPIDP没有有效的抗剂治疗方法.
研究的目的:
- 调查铜 (II) (Cu) 的潜在神经保护作用,以防止TOCP诱导的急性体内神经毒性.
- 评估Cu(II) 预治疗对NTE抑制和OPIDP在成年母中的临床表现的影响.
主要方法:
- 成年被给予不同剂量的TOCP,有或没有Cu (II) 预处理.
- 神经病症向化酶 (NTE) 和胆化酶 (ChE) 活动在大脑和血清中被测量.
- 在21天内评估OPIDP的临床症状,以及肝脏和脏功能的生化参数.
主要成果:
- TOCP的使用显著抑制了大脑NTE活动,达到对照水平的5%左右.
- 在380mg/kg的TOCP中,Cu(II) 预处理显著保留了NTE活性 (约55%) 并防止了OPIDP的临床症状.
- Cu(II) 证明对NTE和血清ChEs具有保护作用,与OPIDP严重性降低相关,而不会引起肝脏或脏毒性.
结论:
- 在体内,Cu (II) 对TOCP诱导的神经毒性和OPIDP表现出显著的神经保护作用.
- 的保护机制似乎与保持NTE活性有关.
- 需要进一步的研究来阐明OPIDP中Cu (II) 的特定神经保护机制.
相关概念视频
Anticholinesterase Agents: Poisoning and Treatment
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...


